Related Experiment Video
Updated: May 6, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
[Targeted therapies in severe asthma: the discovery of new molecules]
J Charriot1, A-S Gamez, M Humbert
1Département des maladies respiratoires, hôpital Arnaud-de-Villeneuve, CHU de Montpellier, 371, avenue du Doyen-Giraud, 34295 Montpellier cedex 5, France.
Abstract:
The pathophysiological mechanisms involved in the chronicity and phenotypic heterogeneity of asthma offer the prospect of new therapeutic opportunities. A better clinical and biological characterisation of selected patients has led to the development of targeted therapies. Studies are under way to demonstrate their efficacy and tolerance and also their impact on the natural history of the disease. This revue aims to examine the therapies, developed during the last ten years, that are based on the immunological mechanisms involved in the pathophysiology of asthma, essentially in its severe form. The rapid expansion of human monoclonal antibodies has allowed testing of various immunological pathways. Anti-IgE, anti- IL-5, and anti-IL-13 strategies seem the most promising. Antagonists to TNF-alpha and I'IL-4 have not succeeded in reducing the events related to severe asthma in a convincing manner. Molecules targeted against thymic stromal lymphopoietin (TSLP) and I'IL-9 are under development. These approaches are involved in the development of therapeutic programmes adapted to the patient's phenotype, that is to say a personalised approach to care.
Insights
New asthma therapies targeting specific immune pathways show promise for severe disease. Personalized treatment approaches are being developed based on patient phenotype and biological characteristics.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Context:
- Asthma exhibits complex pathophysiology, including chronicity and phenotypic heterogeneity.
- Recent advancements in understanding these mechanisms have paved the way for targeted therapeutic strategies.
- Severe asthma, in particular, presents significant challenges in management.
Purpose:
- To review therapies developed over the last decade for asthma, focusing on immunological mechanisms.
- To evaluate the efficacy and impact of these novel treatments on the natural history of severe asthma.
- To highlight the potential of personalized medicine in asthma care.
Summary:
- Human monoclonal antibodies targeting immunological pathways like anti-IgE, anti-IL-5, and anti-IL-13 are most promising for severe asthma.
- Therapeutic strategies involving TNF-alpha and IL-4 antagonists have shown limited success in reducing severe asthma events.
- Emerging therapies targeting thymic stromal lymphopoietin (TSLP) and IL-9 are under investigation.
- The development of these targeted therapies supports a personalized approach to asthma management based on patient phenotype.
Impact:
- These advancements offer new therapeutic opportunities for managing severe asthma.
- The development of targeted therapies facilitates a personalized approach to patient care.
- Future research will focus on demonstrating the efficacy, safety, and disease-modifying potential of these immunotherapies.
More Related Videos
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
05:45A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
Published on: January 16, 2026
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...